|
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
 |
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
A6181112
NCT00372567
|
|
|
Trial Description
Summary A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side effects of taking sunitinib or imatinib for approximately one year. Eligibility Criteria Inclusion Criteria: - Patients with gastrointestinal stromal tumors whose disease has progressed on imatinib 400 mg daily.
Exclusion Criteria: - Current treatment with any chemotherapy other than imatinib.
- Current treatment with any dose of imatinib other than 400 mg
Trial Contact Information
Trial Lead Organizations/Sponsors Pfizer Incorporated | Pfizer CT.gov Call Center | | Study Director |
| Pfizer CT.gov Call Center | | Ph: 1-800-718-1021 |
Trial Sites
|
|
|
|
| U.S.A. |
|
| Illinois |
|
| |
Evanston |
|
| | | | | | | | Pfizer Investigational Site |
|
| |
Glenview |
|
| | | Pfizer Investigational Site |
|
| |
Highland Park |
|
| | | Pfizer Investigational Site |
|
| Missouri |
|
| |
Creve Coeur |
|
| | | | Pfizer Investigational Site |
|
| |
St. Louis |
|
| | | Pfizer Investigational Site |
|
| |
St. Peters |
|
| | | Pfizer Investigational Site |
|
| New York |
|
| |
New York |
|
| | | | Pfizer Investigational Site |
|
| Pennsylvania |
|
| |
Philadelphia |
|
| | | | Pfizer Investigational Site |
|
| Hong Kong |
|
| |
Lai Chi Kok |
|
| | | | Pfizer Investigational Site |
|
| |
Tuen Mun |
|
| | | Pfizer Investigational Site |
|
| Italy |
|
| |
Bologna |
|
| | | | Pfizer Investigational Site |
|
| |
Milano |
|
| | | Pfizer Investigational Site |
|
| |
San Giovanni Rotondo |
|
| | | Pfizer Investigational Site |
|
| Republic of Korea |
|
| |
Seoul |
|
| | | | Pfizer Investigational Site |
|
| Spain |
|
| |
BARCELONA |
|
| | | | Pfizer Investigational Site |
|
| |
VALENCIA |
|
| | | Pfizer Investigational Site |
|
| United Kingdom |
|
| |
Glasgow |
|
| | | | Pfizer Investigational Site |
|
| |
London |
|
| | | Pfizer Investigational Site |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00372567
Information obtained from ClinicalTrials.gov on October 08, 2008 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
